The price, and that is confidential and was negotiated for all in all , 300 zillion doses, is a little less than the $19.50 per shot the United States agreed to purchase a first shipment of 100 million doses of the identical vaccine, in line with what Reuters claimed in November.
The EU document dated Nov. eighteen was circulated internally after the EU announced the supply package of its with Pfizer and the German partner BioNTech of its on Nov. 11.
The EU drug regulator is expected to decide on Monday on acceptance for the Pfizer vaccine following the shot was authorised in several countries, including Britain and also the United States.
On Thursday Belgian state secretary with the spending budget Eva De Bleeker printed on Twitter a table with price tags Belgium would spend pharmaceutical companies for the COVID-19 vaccines of theirs. She retracted the piece of writing shortly after publishing.
In that table the Pfizer vaccine was indicated as costing Belgium twelve euros ($14.6) a dose, top many to believe this was the entire fee agreed by the EU.
Various other vaccines in the family table were furthermore shown with rates lower than rates disclosed by EU sources.
“There is , naturally, a full cost and a price upon delivery,” an EU official involved in talks with vaccine creators told Reuters when asked to clarify the difference between the EU and Belgian prices.
A spokesman for De Bleeker declined to comment on Monday, citing confidentiality needs, but pointed to what De Bleeker told the Belgian parliament last week. In this public hearing, De Beeker stated Belgium’s budgeted price tags were still partial.
Under EU advance purchase deals for COVID-19 vaccines, the bloc agrees upfront payments with companies to secure doses before they are approved. Following approvals, EU governments are able to pay the rest to get reserved doses.
The EU hasn’t revealed the initial payment agreed with Pfizer.
Nevertheless, it stated in October which it paid about 1 billion euros inside downpayments to AstraZeneca, Sanofi and Johnson and Johnson for the shots of theirs, with an additional 1.45 billion euros budgeted for initial payments to Pfizer-BioNTech, Curevac and Moderna.
It’s since agreed source deals with all six organizations and is negotiating a seventh arrangement with Novavax.